+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

P-169 Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients



P-169 Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients



Leukemia Research 37: S99-S100




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064363067

Download citation: RISBibTeXText

DOI: 10.1016/S0145-2126(13)70217-0


Related references

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. Korean Journal of Hematology 45(1): 46-50, 2010

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1): 375-379, 2007

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106(4): 1207-1209, 2005

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Turkish Journal of Gastroenterology 26(1): 42-48, 2015

Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 91(5): 719-720, 2006

The prevalence of JAK2 V617F mutation in myelodysplastic syndrome. 2007

JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation. Srpski Arhiv Za Celokupno Lekarstvo 138(9-10): 614-618, 2011

Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders. American Journal of Hematology 82(6): 458-459, 2007

JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leukemia Research 34(6): 821-823, 2010

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation. Leukemia and Lymphoma 51(10): 1941-1943, 2011

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian Journal of Medical Research 132: 423-427, 2011

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagnostic Molecular Pathology 21(3): 176-183, 2012

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Irish Journal of Medical Science 176(2): 105-109, 2007

JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm. Zhonghua Xue Ye Xue Za Zhi 36(3): 191-195, 2016

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Internal Medicine Journal 38(6): 422-426, 2008